Finally, due to low tumor mutation burden (TMB) in HER2-mutated NSCLC and subsequent low PD-L1 expression, the efficacy of immune checkpoint inhibitor (ICI) monotherapy in pre-treated patients and in first-line ones is limited and controversial [43,44]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.